Skip to main content

Research Repository

Advanced Search

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients

Flume, Patrick; VanDevanter, Donald R.; Morgan, E.E.; Dudley, Michael N.; Loutit, Jeffery S.; Bell, Scott C.; Kerem, Eitan; Fischer, R.; Smyth, Alan R.; Aaron, Shawn D.; Conrad, Douglas; Geller, David E.; Elborn, J. Stuart

Authors

Patrick Flume

Donald R. VanDevanter

E.E. Morgan

Michael N. Dudley

Jeffery S. Loutit

Scott C. Bell

Eitan Kerem

R. Fischer

Profile Image

ALAN SMYTH alan.smyth@nottingham.ac.uk
Professor of Child Health

Shawn D. Aaron

Douglas Conrad

David E. Geller

J. Stuart Elborn



Abstract

Rationale

For patients with cystic fibrosis (CF), the use of inhaled antibiotics has become standard of care to suppress chronic Pseudomonas airways infection. There are limited antibiotic options formulated and approved for inhaled use and antibiotic efficacies attenuate over time, making additional inhaled antibiotic classes desirable. APT-1026 (levofloxacin inhalation solution, LIS) is a fluoroquinolone in development for management of chronic P. aeruginosa airways infection in patients with CF.
Objectives

To compare the safety and efficacy of a 28-day course of treatment with LIS 240 mg or placebo BID in persons ≥ 12 years old with CF and chronic P. aeruginosa infection.
Methods

A multinational, randomized (2:1), double-blinded study of LIS and placebo over 28 days in CF patients ≥ 12 years with chronic P. aeruginosa infection. Time to exacerbation was the primary endpoint. FEV1 (% predicted) and patient-reported quality of life were among secondary endpoints.
Main results

Baseline demographics for 330 subjects (LIS = 220) were similar although significantly more patients randomized to LIS had experienced multiple exacerbations in the year prior to study entry. There was no statistically significant difference in protocol-defined pulmonary exacerbations between treatment arms. Relative change in FEV1% predicted from baseline was significantly greater for patients randomized to LIS compared to those randomized to placebo (mean difference 1.31%, p = 0.01 [95% CI 0.27, 2.34%]). LIS was well-tolerated, with dysguesia the most frequent adverse event.
Conclusions

LIS did not demonstrate a difference in time to next exacerbation when compared to placebo. Reasons for this result are discussed but may be due to an imbalance in the frequency of prior pulmonary exacerbations between the two groups. An improvement in FEV1 (% predicted) at 28 days was observed and LIS was well tolerated. LIS is safe and has a potential role in the management of CF patients with chronic P. aeruginosa.

Citation

Flume, P., VanDevanter, D. R., Morgan, E., Dudley, M. N., Loutit, J. S., Bell, S. C., …Elborn, J. S. (2016). A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. Journal of Cystic Fibrosis, 15, doi:10.1016/j.jcf.2015.12.004

Journal Article Type Article
Acceptance Date Dec 2, 2015
Online Publication Date Feb 4, 2016
Publication Date Jul 1, 2016
Deposit Date Oct 19, 2016
Publicly Available Date Oct 19, 2016
Journal Journal of Cystic Fibrosis
Print ISSN 1569-1993
Electronic ISSN 1873-5010
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 15
DOI https://doi.org/10.1016/j.jcf.2015.12.004
Keywords Cystic fibrosis; Antibiotics; Pseudomonas; Aerosol; Fluoroquinolone
Public URL http://eprints.nottingham.ac.uk/id/eprint/37661
Publisher URL http://www.sciencedirect.com/science/article/pii/S1569199315002763?np=y
Copyright Statement Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by-nc-nd/4.0

Files


Flume_LIS_revision_ trackchanges AS 051015.pdf (1.2 Mb)
PDF

Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by-nc-nd/4.0





You might also like



Downloadable Citations